Athersys Inc
Business Services · Ohio, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
3201 Carnegie Ave, Cleveland, Ohio, 4411...Phone Number
(216) 431-9900Website
www.athersys.comRevenue
$6 MillionStock Symbol
ATHXIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Athersys Inc
Athersys is a biotechnology company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The Company is developing its MultiStem® cell therapy product, a patented, adult-derived "off-the-shelf" stem cell product, initially for disease indications in the neurological, inflammatory and immune, cardiovascular and other critical care indications and has several ongoing clinical trials evaluating this potential regenerative medicine product. Athersys has forged strategic partnerships and a broad network of collaborations to further advance the MultiStem cell therapy toward commercialization.Explore more
Athersys Inc Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Athersys Inc your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Athersys Inc
Check out if Athersys Inc is spiking on competitors!
Funding: Get notified immidiatlly once Athersys Inc has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Athersys Inc, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Athersys Inc recently announced quarterly report
Click to see if Athersys Inc had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Athersys Inc launches new products
Check if Athersys Inc has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Athersys Inc
Compare insights from companies similar to Athersys Inc, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Athersys Inc
$6M
11-50
Public
$264.5M
1995
KR
Kasey RosadoInterim Chief Financial Officer & Board Member
Company Profile Activity
Activity Insights
Athersys Inc is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Athersys Inc is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Athersys Inc.
Athersys Inc financials insights
Gather financial insights about Athersys Inc, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2012
Share Placement
$9M
2013
Debt
$25M
2017
Stock Offering
$23M
2018
Debt
$100M
2020
Share Placement
$7M
2022
Share Placement
$12M
2023
Other Financing Round
$10.4M
Athersys Inc Tech Stack
A closer look at the technologies used by Athersys Inc
See more technologies
Most Recent Scoops
Facilities Relocation / Expansion
Athersys Inc is planning to move offices in July 2024. The move will impact approximately 10 employees at the existing office located at 3201 Carnegie Avenue, Cleveland, OH.
Facilities Relocation/Expansion
Mergers & Acquisitions (M&A)
Mergers & Acquisitions
Left Company
Executive Move
Board of Directors
Left Company
Executive Move
Left Company
Executive Move
Athersys Inc News & Media
Financially strapped Athersys raises $10.4M - cleveland.com
Athersys Inc. said it has raised $10.4 million from investors and licensing partners to extend the company’s liquidity.Athersys Reports Third Quarter 2023 Financial Results and Business Highlights
CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (OTC: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) cell therapy for critical care indications, announced financial results for the three and nine months ended September 30, 2023 and provided a business update. Third Quarter 2023 and Recent Corporate and Operational Highlights: Announced results of a blinded interim analysis of Phase 3 MASTERS-2 clinical trial studying MultiStem for treatment of ischemic stroke indicatingAthersys Extends Near Term Liquidity with Proceeds from Warrant Inducement and Global ARDS License with Healios to Explore Strategic Alternatives
CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (Nasdaq: ATHX), (“Athersys” or the “Company”) a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announces it has entered into a warrant exercise inducement offer letter to raise gross proceeds of up to approximately $3.9 million from the exercise of 28,124,590 warrants and received the first tranche payment of $1.5 million from HEALIOS K.K. (“Healios”) under the acute respiratory distrAthersys Reports Interim Analysis Results of MASTERS-2 Clinical Study with MultiStem in Ischemic Stroke, Signs Memorandum of Understanding (MOU) for Global ARDS License with Healios
CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (Nasdaq: ATHX), a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announces that the independent data safety monitoring board (DSMB) has completed a pre-planned interim analysis of the Company’s ongoing Phase 3 MASTERS-2 pivotal clinical trial evaluating MultiStem® for the treatment of acute moderate-to-severe ischemic stroke, and concluded that the current sample size of 300 patients
Read more news
Top Business Services Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Athersys Inc
Sign Up For FreeTo access detailed company insights
Athersys is a biotechnology company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The Company is developing its MultiStem® cell therapy product, a patented, adult-derived "off-the-shelf" stem cell product, initially for disease indications in the neurological, in... Read More
